PH24716A - Stabilized human tissue plasminogen activator compositions - Google Patents
Stabilized human tissue plasminogen activator compositionsInfo
- Publication number
- PH24716A PH24716A PH34602A PH34602A PH24716A PH 24716 A PH24716 A PH 24716A PH 34602 A PH34602 A PH 34602A PH 34602 A PH34602 A PH 34602A PH 24716 A PH24716 A PH 24716A
- Authority
- PH
- Philippines
- Prior art keywords
- plasminogen activator
- human tissue
- tissue plasminogen
- activator compositions
- stabilized human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/811,081 US4777043A (en) | 1985-12-17 | 1985-12-17 | Stabilized human tissue plasminogen activator compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
PH24716A true PH24716A (en) | 1990-10-01 |
Family
ID=25205495
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PH34602A PH24716A (en) | 1985-12-17 | 1986-12-16 | Stabilized human tissue plasminogen activator compositions |
Country Status (23)
Country | Link |
---|---|
US (2) | US4777043A (pt) |
EP (1) | EP0228862B1 (pt) |
JP (2) | JPH0714886B2 (pt) |
KR (1) | KR950010322B1 (pt) |
AT (1) | ATE79273T1 (pt) |
AU (1) | AU600246B2 (pt) |
DD (1) | DD255477A5 (pt) |
DE (2) | DE3642960A1 (pt) |
DK (1) | DK174203B1 (pt) |
ES (1) | ES2044840T3 (pt) |
FI (1) | FI88873C (pt) |
FR (1) | FR2591485B1 (pt) |
GB (1) | GB2184354B (pt) |
GR (1) | GR3006078T3 (pt) |
HU (1) | HU200101B (pt) |
IE (1) | IE59060B1 (pt) |
IL (1) | IL80904A (pt) |
MY (1) | MY102185A (pt) |
NO (1) | NO168988C (pt) |
NZ (1) | NZ218612A (pt) |
PH (1) | PH24716A (pt) |
PT (1) | PT83933B (pt) |
ZA (1) | ZA869457B (pt) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3687255T2 (de) * | 1985-09-10 | 1993-05-06 | Eisai Co Ltd | Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung. |
JPH0672105B2 (ja) * | 1985-10-02 | 1994-09-14 | 持田製薬株式会社 | 血栓溶解剤及びその製法 |
US5453363A (en) * | 1985-10-23 | 1995-09-26 | Boehringer Mannheim Gmbh | Process for the activation of t-PA or Ing after genetic expression in prokaryotes |
US5034225A (en) * | 1985-12-17 | 1991-07-23 | Genentech Inc. | Stabilized human tissue plasminogen activator compositions |
JP2708749B2 (ja) | 1987-08-10 | 1998-02-04 | エーザイ株式会社 | 修飾型tPA含有注射用組成物 |
EP0317376B2 (fr) * | 1987-10-23 | 1996-04-03 | Centre Regional De Transfusion Sanguine De Lille | Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques |
US4898826A (en) * | 1987-12-10 | 1990-02-06 | Invitron Corporation | Method to solubilize tissue plasminogen activator |
HU206367B (en) * | 1988-04-30 | 1992-10-28 | Sandoz Ag | Process for producing acid addition salts of steroid carboxylic acid-amidated taurine and glycine, as well as pharmaceutical compositions comprising such salts |
US4980165A (en) * | 1989-01-27 | 1990-12-25 | Genetics Institute, Inc. | Pharmaceutical formulations of plasminogen activator proteins |
DE3903581A1 (de) * | 1989-02-07 | 1990-08-16 | Boehringer Mannheim Gmbh | Gewebs-plasminogenaktivator-derivat |
US6207151B1 (en) * | 1989-09-21 | 2001-03-27 | Mitsui Chemicals Inc. | Aqueous solution of t-PA |
JP2520975B2 (ja) * | 1989-09-21 | 1996-07-31 | 三井東圧化学株式会社 | 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤 |
DE3942144A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | Stabilisierung von k1k2p pro |
DE3942141A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | K2p pro-stabilisierung |
DE3942142A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | Stabilisierung von glykosyliertem t-pa |
DE3942145A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | T-pa-solubilisierung |
DE3942143A1 (de) * | 1989-12-20 | 1991-06-27 | Boehringer Mannheim Gmbh | T-pa pro stabilisierung |
US5358708A (en) * | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
US5656730A (en) * | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
DE19606551C2 (de) * | 1996-02-22 | 2000-06-08 | Basotherm Gmbh | rt-PA zur Prävention des Nachstars nach Kataraktoperation |
US5972912A (en) * | 1998-12-17 | 1999-10-26 | S.P. Pharmaceuticals | Method for lyophilizing ifosfamide |
US6586574B1 (en) | 1999-08-17 | 2003-07-01 | Nn A/S | Stabilization of freeze-dried cake |
AU6558400A (en) * | 1999-08-17 | 2001-03-13 | Novo Nordisk A/S | Stabilisation of freeze-dried cake |
AU781023B2 (en) | 1999-11-04 | 2005-04-28 | Genentech Inc. | Reversed-phase HPLC assay for plasminogen activators |
CA2403962C (en) | 2000-03-31 | 2009-12-15 | Kirin Beer Kabushiki Kaisha | Powdery preparation for transmucosal administration comprising a medicine of high molecular weight and exhibiting an improved storage stability |
US20030077682A1 (en) * | 2001-09-07 | 2003-04-24 | Hung Paul Porwen | Human tissue urokinase type plasminogen activator formulation |
US20110179558A1 (en) * | 2009-07-29 | 2011-07-28 | International Enviroguard Systems, Inc. | Breathable Protective Fabric and Garment |
AU2014236938B2 (en) * | 2013-03-14 | 2018-12-20 | Allergan, Inc. | Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK98833C (da) * | 1961-04-25 | 1964-05-25 | Novo Terapeutisk Labor As | Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger. |
DE3273732D1 (en) * | 1982-12-30 | 1986-11-20 | Kowa Co | Method of producing a tissue plasminogen activator and composition comprising same |
JPS59196824A (ja) * | 1983-04-21 | 1984-11-08 | Kowa Co | 吸着防止剤 |
DE3584902D1 (de) * | 1984-02-29 | 1992-01-30 | Asahi Chemical Ind | Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren. |
IL78571A (en) * | 1985-04-22 | 1991-06-30 | Genentech Inc | Human tissue plasminogen activator mutants resistant to enzymatic cleavage resulting in two-chain form |
US4929444A (en) * | 1985-05-28 | 1990-05-29 | Burroughs Wellcome Co. | Low pH pharmaceutical formulation containing t-PA |
NL8601354A (nl) * | 1985-05-28 | 1986-12-16 | Wellcome Found | Nieuwe samenstelling. |
ZW14486A1 (en) * | 1985-07-29 | 1986-10-22 | Smithkline Beckman Corp | Pharmaceutical dosage unit |
DE3687255T2 (de) * | 1985-09-10 | 1993-05-06 | Eisai Co Ltd | Einen gewebe-plasminogen-aktivator enthaltende zusammensetzung. |
JPH0672105B2 (ja) * | 1985-10-02 | 1994-09-14 | 持田製薬株式会社 | 血栓溶解剤及びその製法 |
DE3537708A1 (de) * | 1985-10-23 | 1987-04-23 | Boehringer Mannheim Gmbh | Verfahren zur aktivierung von t-pa nach expression in prokaryonten |
JPS62120321A (ja) * | 1985-11-20 | 1987-06-01 | Eisai Co Ltd | tPA含有医薬組成物 |
JPS62283932A (ja) * | 1986-05-29 | 1987-12-09 | Green Cross Corp:The | 組織プラスミノ−ゲンアクチベ−タの乾燥製剤 |
-
1985
- 1985-12-17 US US06/811,081 patent/US4777043A/en not_active Expired - Lifetime
-
1986
- 1986-12-08 IL IL80904A patent/IL80904A/xx not_active IP Right Cessation
- 1986-12-12 NZ NZ218612A patent/NZ218612A/xx unknown
- 1986-12-15 PT PT83933A patent/PT83933B/pt unknown
- 1986-12-16 EP EP86309811A patent/EP0228862B1/en not_active Expired - Lifetime
- 1986-12-16 AU AU66610/86A patent/AU600246B2/en not_active Expired
- 1986-12-16 FR FR8617593A patent/FR2591485B1/fr not_active Expired
- 1986-12-16 HU HU865225A patent/HU200101B/hu unknown
- 1986-12-16 NO NO865079A patent/NO168988C/no not_active IP Right Cessation
- 1986-12-16 DD DD86297695A patent/DD255477A5/de unknown
- 1986-12-16 PH PH34602A patent/PH24716A/en unknown
- 1986-12-16 DK DK198606057A patent/DK174203B1/da not_active IP Right Cessation
- 1986-12-16 DE DE19863642960 patent/DE3642960A1/de not_active Ceased
- 1986-12-16 KR KR1019860010747A patent/KR950010322B1/ko not_active IP Right Cessation
- 1986-12-16 IE IE327986A patent/IE59060B1/en not_active IP Right Cessation
- 1986-12-16 ES ES86309811T patent/ES2044840T3/es not_active Expired - Lifetime
- 1986-12-16 DE DE8686309811T patent/DE3686410T2/de not_active Expired - Lifetime
- 1986-12-16 GB GB8629981A patent/GB2184354B/en not_active Revoked
- 1986-12-16 AT AT86309811T patent/ATE79273T1/de not_active IP Right Cessation
- 1986-12-17 JP JP61302767A patent/JPH0714886B2/ja not_active Expired - Lifetime
- 1986-12-17 FI FI865159A patent/FI88873C/fi not_active IP Right Cessation
- 1986-12-17 ZA ZA869457A patent/ZA869457B/xx unknown
-
1987
- 1987-10-01 MY MYPI87002760A patent/MY102185A/en unknown
-
1988
- 1988-03-28 US US07/173,854 patent/US4908205A/en not_active Expired - Lifetime
-
1992
- 1992-10-26 GR GR920402407T patent/GR3006078T3/el unknown
-
1994
- 1994-08-04 JP JP6183274A patent/JPH07173076A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2184354B (en) | Stabilized human tissue plasminogen activator compositions | |
GR3006630T3 (pt) | ||
GR3007385T3 (pt) | ||
IL140140A0 (en) | Thyroid hormone analogues and methods for their preparation | |
IL85189A (en) | Beta-alkyl substituted melatonins,their preparation and pharmaceutical compositions containing them | |
HUT41002A (en) | Process for preparing anticonvulsives | |
MY102026A (en) | Antiasthmatic. | |
ZA891242B (en) | 24r-scymnol,and preparation and use thereof | |
HK135494A (en) | Azelastin embonate, process for its preparation and pharmaceutical compositions containing azelastin embonate as the active ingredient | |
AU1235288A (en) | Antidepressant compositions | |
GR3005231T3 (pt) | ||
GR3003132T3 (en) | Pharmaceutical compositions having healing activity | |
IL68195A (en) | Dermatological preparations containing as active ingredients 1alpha-hydroxycholecalciferol or 1alpha,25-dihydroxy-cholecalciferol | |
ES8706441A1 (es) | Procedimiento para preparar una composicion farmaceutica a base de sulpirida y un progestageno. | |
AU563031C (en) | Human Tissue Plasminogen Activator | |
AU563031B2 (en) | Human tissue plasminogen activator | |
HU910063D0 (en) | Process for the production of preparations containing synergetic combination of active agents of natural origin, usable for selective decreasing of blood lipoids |